Showing results (51-60 of 222) with videos related to
Sort By:
Pageof 23
Investigational New Drugs|October 17, 2007
A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumorsElisabeth I Heath, Keith Bible, Robert E Martell, et al.Gut|January 1, 1993
Role of interleukin-6 in mediating the acute phase protein response and potential as an early means of severity assessment in acute pancreatitisD I Heath, A Cruickshank, M Gudgeon, et al.Investigational New Drugs|October 6, 2021
Phase Ia dose escalation study of OBP-801, a cyclic depsipeptide class I histone deacetylase inhibitor, in patients with advanced solid tumorsElisabeth I Heath, Amy Weise, Ulka Vaishampayan, et al.Pancreas|May 1, 1995
The relationship between pancreatic enzyme release and activation and the acute-phase protein response in patients with acute pancreatitisD I Heath, A Cruickshank, A M Gudgeon, et al.Computer Methods in Applied Mechanics and Engineering|August 21, 2023
A stabilized linear finite element method for anisotropic poroelastodynamics with application to cardiac perfusionNamshad Thekkethil, Simone Rossi, Hao Gao, et al.JCO Oncology Practice|July 11, 2023
Using Music as a Tool for Distress Reduction During Cancer Chemotherapy TreatmentFelicity W K Harper, Allison S Heath, Tanina Foster Moore, et al.Gut|September 1, 1994
Trypsinogen activation peptides (TAP) concentrations in the peritoneal fluid of patients with acute pancreatitis and their relation to the presence of histologically confirmed pancreatic necrosisD I Heath, C Wilson, A M Gudgeon, et al.JCO Oncology Practice|June 24, 2025
What About the Caregivers? Music Medicine as a Tool for Improving Psychological Well-Being Among Caregivers During Cancer Chemotherapy TreatmentFelicity W K Harper, Tanina Foster Moore, Allison S Heath, et al.Hematological Oncology|May 1, 1989
Angiotropic large cell lymphoma (ALCL): morphological, immunohistochemical and genotypic studies with analysis of previous reportsP Domizio, P A Hall, F Cotter, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC)Shirish M Gadgeel, John C Ruckdeschel, Elisabeth I Heath, et al.Pageof 23